JAN 2 3 2008

A BILL FOR AN ACT

RELATING TO LIFE SCIENCES.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

- 1 SECTION 1. The legislature finds that the life sciences
- 2 industry plays a significant role in the diversification and
- 3 therefore, the sustainability of Hawaii's economy. Ground-
- 4 breaking medical studies have already been conducted in Hawaii
- 5 by the Cancer Research Center and Pacific Health Research
- 6 Institute.
- 7 Hawaii's unique location and ethnic diversity provide
- 8 indispensable advantages to companies conducting clinical
- 9 trials. Life sciences companies that conduct these trials often
- 10 create more and higher paying jobs that will help to keep our
- 11 local talent employed in the State. In addition, conducting
- 12 these trials in Hawaii will put our State on the cutting edge of
- 13 drug development, bringing in research funding from Asia and
- 14 North America.
- 15 Providing a specific tax boost would particularly help
- 16 Hawaii companies that are pioneering pharmaceutical and other

1	health products at a time that they are entering phases three	
2	and four of their clinical trials.	
3	The purpose of this Act is to advance the important	
4	specialization components of the Hawaii life sciences road map	
5	by providing a tax incentive for life sciences companies to	
6	conduct clinical trials in Hawaii.	
7	SECTION 2. Chapter 235, Hawaii Revised Statutes, is	
8	amended by adding a new section to be appropriately designated	
9	and to read as follows:	
10	"§235- Clinical trials; income tax credit. (a) Any law	
11	to the contrary notwithstanding, there shall be allowed to each	
12	taxpayer subject to the taxes imposed by this chapter, an incom	
13	tax credit that shall be deductible from the taxpayer's net	
14	income tax liability, if any, imposed by this chapter for the	
15	taxable year in which the credit is properly claimed. The	
16	amount of the credit shall be:	
17	(1) Fifteen per cent of the qualified clinical trial costs	
18	incurred by a qualified clinical trial in any county	
19	of the State with a population of over seven hundred	
20	thousand: or	

Twenty per cent of the qualified clinical trial costs

incurred by a qualified clinical trial in any county

2008-0898 SB SMA.doc

(2)

21

22

1	of the State with a population of seven hundred
2	thousand or less.
3	A qualified clinical trial occurring in more than one county may
4	prorate its expenditures based upon the amounts spent in each
5	county; provided that the population bases differ enough to
6	change the percentage of tax credit.
7	In the case of a partnership, S corporation, estate, or
8	trust, the tax credit allowable is for qualified clinical trial
9	costs incurred by the entity for the taxable year. The cost
10	upon which the tax credit is computed shall be determined at the
11	entity level. Distribution and share of credit shall be
12	determined by rule.
13	If a deduction is taken under section 179 (with respect to
14	election to expense depreciable business assets) of the Internal
15	Revenue Code of 1986, as amended, no tax credit shall be allowed
16	for those costs for which the deduction is taken.
17	The basis for eligible property for depreciation of accelerated
18	cost recovery system purposes for state income taxes shall be
19	reduced by the amount of credit allowable and claimed.
20	(b) The credit allowed under this section shall be claimed
21	against the net income tax liability for the taxable year. For
22	the purposes of this section, "net income tax liability" means
	2008-0898 SB SMA.doc

1	net incom	e tax liability reduced by all other credits allowed
2	under this chapter.	
3	(c)	If the tax credit under this section exceeds the
4	taxpayer'	s income tax liability, the excess of credits over
5	liability	shall be refunded to the taxpayer; provided that no
6	refunds or payment on account of the tax credits allowed by thi	
7	section shall be made for amounts less than \$1. All claims,	
8	including	any amended claims, for tax credits under this section
9	shall be filed on or before the end of the twelfth month	
10	following the close of the taxable year for which the credit ma	
11	be claimed. Failure to comply with the foregoing provision	
12	shall constitute a waiver of the right to claim the credit.	
13	(d)	To qualify for this tax credit, a clinical trial
14	shall:	
15	(1)	Meet the definition of a qualified clinical trial
16		specified in subsection (1);
17	(2)	Have qualified clinical trial costs totaling at least
18		\$200,000;
19	(3)	Provide evidence of reasonable efforts to hire local
20		researchers and staff; and
21	(4)	Provide evidence of financial or in-kind contributions
22		or educational or workforce development efforts, in

1	partnership with related trade and business
2	development organizations, educational institutions,
3	or both, toward the furtherance of the local science,
4	technology and health industry.
5	(e) On or after July 1, 2008, no qualified clinical trial
6	cost that has been financed by investments for which a credit
7	was claimed by any taxpayer pursuant to section 235-110.9 shall
8	be eligible for credits under this section.
9	(f) To receive the tax credit, the taxpayer shall first
10	pre-qualify the clinical trial for the credit by registering
11	with the department of taxation. Failure to comply with this
12	provision may constitute a waiver of the right to claim the
13	credit.
14	(g) The director of taxation shall prepare forms as may be
15	necessary to claim a credit under this section. The director
16	may also require the taxpayer to furnish information to
17	ascertain the validity of the claim for credit made under this
18	section and may adopt rules necessary to effectuate the purposes
19	of this section pursuant to chapter 91.
20	(h) Every taxpayer claiming a tax credit under this
21	section for a qualified clinical trial, no later than ninety
22	days following the end of each taxable year in which qualified
	2008-0898 SB SMA.doc

1	clinical trial costs were expended, shall submit a written,	
2	sworn sta	tement to the department of taxation, identifying:
3	(1)	All qualified clinical trial costs as provided by
4		subsection (a), if any, incurred in the previous
5		taxable year;
6	(2)	The amount of tax credits claimed pursuant to this
7		section, if any, in the previous taxable year; and
8	(3)	The number of total hires versus the number of local
9		hires by category (i.e., department) and by county.
10	(i)	The department of taxation shall:
11	(1)	Maintain records of the names of the taxpayers and
12		qualified clinical trials thereof claiming the tax
13		credits under subsection (a);
14	(2)	Obtain and total the aggregate amounts of all
15		qualified clinical trial costs per qualified clinical
16		trial and per qualified clinical trial per taxable
17		year; and
18	(3)	Provide a letter to the director of taxation
19		specifying the amount of the tax credit per qualified
20		clinical trial for each taxable year that a tax credit
21		is claimed and the cumulative amount of the tax credit
22		for all years claimed.

- 1 Upon each determination required under this subsection, the
- 2 department of taxation shall issue a letter to the taxpayer,
- 3 regarding the qualified clinical trial, specifying the qualified
- 4 clinical trial costs and the tax credit amount qualified for in
- 5 each taxable year a tax credit is claimed. The taxpayer for
- 6 each qualified clinical trial shall file the letter with the
- 7 taxpayer's tax return for the qualified clinical trial to the
- 8 department of taxation. The director of taxation may audit and
- 9 adjust the tax credit amount to conform to the information filed
- 10 by the taxpayer.
- 11 (j) Total tax credits claimed per qualified clinical trial
- 12 shall not exceed \$8,000,000.
- (k) Qualified clinical trials shall comply with
- 14 subsections (d), (e), (f), and (h).
- (1) For the purposes of this section:
- "Qualified Clinical trials" means a research study,
- 17 conducted within the State, to answer specific questions about
- 18 vaccines, new therapies or new ways of using known treatments to
- 19 determine whether new drugs or treatments are both safe and
- 20 effective.
- 21 "Qualified clinical trial costs" means the costs incurred
- 22 by a qualified clinical trial within the State that are subject



1	to the ge	neral excise tax under chapter 237 or income tax under	
2	this chap	ter and that have not been financed by any investments	
3	for which	a credit was or will be claimed pursuant to section	
4	235-110.9	. Qualified clinical trial costs include but are not	
5	limited to:		
6	(1)	Costs associated with planning, designing, executing	
7		and analyzing a qualified clinical trial;	
8	(2)	Data, blood, and tissue sampling and analysis,	
9		statistical analysis;	
10	(3)	Hospital, physician, and nursing costs;	
11	(4)	Wages or salaries of researchers and staff;	
12	(5)	Costs of imaging and related technical services;	
13	(6)	Costs associated with clinical trial participants;	
14	<u>(7)</u>	Rentals and fees for use of local facilities and	
15		research laboratories; and	
16	(8)	Other direct clinical trial costs specified by the	
17		department in consultation with the department of	
18		taxation."	
19	SECT	ION 3. New statutory material is underscored.	

- 1 SECTION 4. This Act, upon its approval, shall apply to
- 2 taxable years beginning after December 31, 2007.

3

INTRODUCED BY:

Report Title:

Clinical Trials; Tax Credit

Description:

Provides for an income tax credit amounting to fifteen per cent of qualified clinical trials incurred, in any county of Hawaii with a population over 700,000, and twenty per cent in any county with a population under 700,000. Establishes criteria to qualify for the tax credit. Caps credit at \$8,000,000 per clinical trial.